-
Uncategorized2 weeks ago
2026 Orphan Drugs Report: A safe(r) passage amid stormy waters?
Orphan drugs remain commercially durable, strategically relevant and supported by a strong pipeline Read More
-
Uncategorized2 weeks agoSTAT+: Executives reveal tech initiatives at Summa Health, eight months after General Catalyst acquisition
COLUMBUS, Ohio — People across northeast Ohio are now receiving AI phone calls to help them prep for surgery and navigate care after they leave the...
-
Uncategorized2 weeks ago
Obesity Davids and Goliaths face off at ADA 2026
The American Diabetes Association’s annual congress will feature a superstar lineup, including weight loss giants Eli Lilly and Novo Nordisk. But several scrappy biotechs will also...
-
Uncategorized2 weeks ago
Biohaven looks to obesity to bounce back from run of clinical and regulatory failures
After trial flops in spinal muscular atrophy, depression and bipolar disorder—and a costly rare disease drug rejection—Biohaven is undergoing a reset, recasting its former SMA candidate...
-
Uncategorized2 weeks ago
StockWatch: Agilent Shares Jump on Better than Expected Quarterly Results
A strong quarterly earnings report that beat analyst expectations, growth that extended into core pharma and biotech tools, plus improved investor guidance on revenue, operating margin,...
-
Uncategorized2 weeks ago
Decoding the origins of cellular self-organization for engineered biology
Nature Biotechnology, Published online: 01 June 2026; doi:10.1038/s41587-026-03161-w This Perspective positions cellular self-organization as a foundational principle for the origin of multicellular life and discusses how...
-
Uncategorized2 weeks agoSTAT+: A standing ovation for RevMed, and caution for Akeso
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions here. ...
-
Uncategorized2 weeks agoUltra-low doses could bring costly cancer treatments to more patients in poorer countries
CHICAGO — What if the trick to getting cancer immunotherapy to parts of the world that can’t access it is simply lowering the dose? A lower-cost...
-
Uncategorized2 weeks ago
ASCO: Telix tees up pivotal test for Pluvicto challenger while eyeing ‘white space’ on radiopharma canvas
David Cade, the chief medical officer of Melbourne-based Telix Pharmaceuticals, traveled a long way to the American Society of Clinical Oncology meeting in Chicago with a...
-
Uncategorized2 weeks ago
ASCO: Akeso’s VEGF/PD-1 boosts lung cancer survival, relieving pressure on US partner Summit
Analysts, investors and partner Summit Therapeutics had all been keenly awaiting the overall survival update, after previous data from Akeso’s HARMONi-6 trial left them wanting.
Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins
STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America
